Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SMMT with free AI briefings, catalyst countdowns, and dilution alerts.

SMMT · Summit Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $11.82, 28% below $16.39, its close on the day of its Sep 29 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$2.6B Cash, Pro Forma
52.4mo Cash Runway
26.7% Short Interest
$29.45 Analyst Target (13)
Follow SMMT by email Get an email when SMMT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SMMT, unsubscribe in one click. Privacy

📣 What SMMT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ligufalimab (AK117) Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) Phase 3 · NCT07264075 Recruiting
Ivonescimab RP3D Metastatic Urothelial Carcinoma Phase 2/3 · NCT07815665 Recruiting
Ivonescimab (AK112) Non-Small Cell Lung Cancer Phase 3 · NCT06767514 Recruiting
Ivonescimab Dose 2 Metastatic Urothelial Carcinoma Phase 2/3 · NCT07815665 Recruiting
Ivonescimab Dose 1 Metastatic Urothelial Carcinoma Phase 2/3 · NCT07815665 Recruiting
Ridinilazole Clostridioides Difficile Infection Phase 3 · NCT03595553 Completed
Vancomycin Clostridioides Difficile Infection Phase 3 · NCT03595553 Completed
Nebivolol Ophthalmic Suspension 0.5 Percent Open-Angle Glaucoma Phase 2 · NCT04910100 Completed
Nebivolol Ophthalmic Suspension 1 Percent Open-Angle Glaucoma Phase 2 · NCT04910100 Completed
Cadonilimab Renal Cell Carcinoma, Clear Cell Phase 2 · NCT07877194 Not yet recruiting
Osimertinib Non-Small Cell Lung Cancer Phase 1/2 · NCT07535437 Recruiting
Nab-paclitaxel Non Small Cell Lung Cancer Phase 2 · NCT07234877 Not yet recruiting
Timolol Ophthalmic Solution 0.5 Percent Open-Angle Glaucoma Phase 2 · NCT04910100 Completed
Timolol Ophthalmic Suspension 0.5 Percent Open-Angle Glaucoma Phase 2 · NCT04910100 Completed
Zoldonrasib Advanced Solid Tumors Phase 1/2 · NCT07397338 Recruiting
Datopotamab Deruxtecan Non-Small Cell Lung Cancer Phase 1/2 · NCT07535437 Recruiting

Also used in these trials (approved or third-party drugs, not SMMT's own candidates): Pembrolizumab, Oxaliplatin, Enfortumab Vedotin, Ipilimumab, Leucovorin, Paclitaxel, Pemetrexed Disodium, Daraxonrasib, Bevacizumab, Capecitabine, Carboplatin, Cetuximab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SMMT had $629.8M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $2.6B pro forma, before operating spending after that date:

It burns about $150.5M/quarter from operations, an estimated runway of 52.4 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SMMT files for a raise →

👥 Who Owns SMMT

Insiders 80.8% Institutions (379 holders) 17.1% Public and other holders 2.1%
HolderTypeShares% of sharesAs of
Robert W Duggan
Co-Chief Executive Officer, Director, 10 · +16.19M options
Insider 610,515,809 76.34% 2026-11-16
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10 · +10.81M options
Includes shares also reported by Robert W Duggan, counted once
Insider 610,515,809 76.34% 2026-11-16
Baker Bros. Advisors, LP Institution (13F) 32,786,348 4.10% 2026-09-30
Yu Xia
Director · +40,438 options
Insider 32,057,147 4.01% 2025-10-21
Blackrock Inc. Institution (13F) 10,363,750 1.30% 2026-09-30
FMR, LLC Institution (13F) 8,136,745 1.02% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 7,230,441 0.90% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 6,717,642 0.84% 2026-09-30
State Street Corporation Institution (13F) 6,093,474 0.76% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 5,296,215 0.66% 2026-09-30
Citadel Advisors Llc Institution (13F) 3,783,589 0.47% 2026-09-30
Geode Capital Management, LLC Institution (13F) 3,489,224 0.44% 2026-09-30

Share count 799,763,918 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-16
filed 2026-11-16
DUGGAN ROBERT W
Option exercise (M) 500,000 $1.06 531,000
2026-11-16
filed 2026-11-16
DUGGAN ROBERT W
Option exercise (M) 500,000 – –
2026-11-16
filed 2026-11-16
Zanganeh Mahkam
Option exercise (M) 500,000 $1.06 531,000
2026-11-16
filed 2026-11-16
Zanganeh Mahkam
Option exercise (M) 500,000 – –
2026-11-16
filed 2026-11-16
Soni Manmeet Singh
Option exercise (M) 100,000 $1.37 3,224,375

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-11-14 ivonescimab BLA -7.9% — —

Browse all historical PDUFA outcomes →

Get the full SMMT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SMMT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.